Global COPD Medicine Market

COPD Medicine Comprehensive Study by Type (Emphysema, Chronic bronchitis), Route of Administration (Inhalation, Enteral, Parenteral), Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy, Others), Treatment Type (Drugs, 1. Bronchodilator Monotherapy, • Short-Acting Beta2-Agonists (SABAs), • Long-Acting Beta2-Agonists (LABAs), • Anti-Cholinergic Agents, 2. Anti-Inflammatory Drugs, • Oral and Inhaled Corticosteroids, • Anti-Leukotrienes, Surgery, • Lung Volume Reduction Surgery (LVRS), • Lung Transplant, • Bullectomy, • Others, Oxygen Therapy), Drug Class (Bronchodilators drugs, Steroids drugs, Combination) Players and Region - Global Market Outlook to 2026

COPD Medicine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is COPD Medicine?
Chronic obstructive pulmonary disease (COPD) is a progressive serious lung disease that causes shortness of breath at the start with exertion and predisposes to exacerbations & serious health problem. Its symptoms include issue in respiration, cough, mucus formation & wheezing. individuals with COPD are at increased risk of developing lung cancer, cardiovascular disease & many different health problems. COPD isn't curable, however treatment will relieve symptoms, improve quality of life and reduce the risk of death. The more familiar terms “chronic bronchitis” and “emphysema” have usually been used as labels for the condition.

The market study is broken down and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analysts at AMA Research estimates that Players from Switzerland will contribute to the maximum growth of Global COPD Medicine market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GSK (United Kingdom), AstraZeneca (United Kingdom), Boehringer Ingelheim (Germany), Roche (Switzerland), Novartis (Switzerland), Teva (Israel), Chiesi (Italy), Mylan (United States), Sumitomo Dainippon (Japan) and Merck (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Dr. Reddy’s Laboratories Ltd (India), F. Hoffmann-La Roche Ltd (Switzerland) and Abbott (United States).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global COPD Medicine market by Type, Application and Region.

On the basis of geography, the market of COPD Medicine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Type, the sub-segment i.e. Emphysema will boost the COPD Medicine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Inhalation will boost the COPD Medicine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital pharmacy will boost the COPD Medicine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Type, the sub-segment i.e. Drugs will boost the COPD Medicine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Bronchodilators drugs will boost the COPD Medicine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

European Commission approves Bevespi Aerosphere developed by AstraZeneca


Market Trend
  • Rapid urbanization

Market Drivers
  • High pollution levels as a result of intense industrial activities
  • Excessive smoking
  • Rapid adoption of sedentary lifestyle
  • Growing prevalence of respiratory disorders
  • Technological advancements
  • New product launches
  • Increasing demand for home care therapeutic devices

Opportunities
  • Developing healthcare infrastructure in developing countries
  • People with COPD are at increased risk of developing heart disease, lung cancer, and several other health conditions

Restraints
  • Stringent government regulations
  • Patent Expiry of Branded Products and Availability of Generic Equivalents

Challenges
  • Patient education
  • Self-management
  • Medication adherence
  • Comorbidity management


Key Target Audience
Biotechnology companies, Research institutes, Pharmaceutical companies, Hospitals and clinics, Ambulatory surgical centers, Academic institutes, Government organizations, Raw materials Vendors, Downstream vendors and end-users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Emphysema
  • Chronic bronchitis

By Route of Administration
  • Inhalation
  • Enteral
  • Parenteral

By Distribution Channel
  • Hospital pharmacy
  • Retail pharmacy
  • Online pharmacy
  • Others

By Treatment Type
  • Drugs
  • 1. Bronchodilator Monotherapy
  • • Short-Acting Beta2-Agonists (SABAs)
  • • Long-Acting Beta2-Agonists (LABAs)
  • • Anti-Cholinergic Agents
  • 2. Anti-Inflammatory Drugs
  • • Oral and Inhaled Corticosteroids
  • • Anti-Leukotrienes
  • Surgery
  • • Lung Volume Reduction Surgery (LVRS)
  • • Lung Transplant
  • • Bullectomy
  • • Others
  • Oxygen Therapy

By Drug Class
  • Bronchodilators drugs
  • Steroids drugs
  • Combination

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High pollution levels as a result of intense industrial activities
      • 3.2.2. Excessive smoking
      • 3.2.3. Rapid adoption of sedentary lifestyle
      • 3.2.4. Growing prevalence of respiratory disorders
      • 3.2.5. Technological advancements
      • 3.2.6. New product launches
      • 3.2.7. Increasing demand for home care therapeutic devices
    • 3.3. Market Challenges
      • 3.3.1. Patient education
      • 3.3.2. Self-management
      • 3.3.3. Medication adherence
      • 3.3.4. Comorbidity management
    • 3.4. Market Trends
      • 3.4.1. Rapid urbanization
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global COPD Medicine, by Type, Route of Administration, Distribution Channel, Treatment Type, Drug Class and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global COPD Medicine (Value)
      • 5.2.1. Global COPD Medicine by: Type (Value)
        • 5.2.1.1. Emphysema
        • 5.2.1.2. Chronic bronchitis
      • 5.2.2. Global COPD Medicine by: Type (Value)
        • 5.2.2.1. Emphysema
        • 5.2.2.2. Chronic bronchitis
      • 5.2.3. Global COPD Medicine by: Route of Administration (Value)
        • 5.2.3.1. Inhalation
        • 5.2.3.2. Enteral
        • 5.2.3.3. Parenteral
      • 5.2.4. Global COPD Medicine by: Distribution Channel (Value)
        • 5.2.4.1. Hospital pharmacy
        • 5.2.4.2. Retail pharmacy
        • 5.2.4.3. Online pharmacy
        • 5.2.4.4. Others
      • 5.2.5. Global COPD Medicine by: Treatment Type (Value)
        • 5.2.5.1. Drugs
        • 5.2.5.2. 1. Bronchodilator Monotherapy
        • 5.2.5.3. • Short-Acting Beta2-Agonists (SABAs)
        • 5.2.5.4. • Long-Acting Beta2-Agonists (LABAs)
        • 5.2.5.5. • Anti-Cholinergic Agents
        • 5.2.5.6. 2. Anti-Inflammatory Drugs
        • 5.2.5.7. • Oral and Inhaled Corticosteroids
        • 5.2.5.8. • Anti-Leukotrienes
        • 5.2.5.9. Surgery
        • 5.2.5.10. • Lung Volume Reduction Surgery (LVRS)
        • 5.2.5.11. • Lung Transplant
        • 5.2.5.12. • Bullectomy
        • 5.2.5.13. • Others
        • 5.2.5.14. Oxygen Therapy
      • 5.2.6. Global COPD Medicine by: Drug Class (Value)
        • 5.2.6.1. Bronchodilators drugs
        • 5.2.6.2. Steroids drugs
        • 5.2.6.3. Combination
      • 5.2.7. Global COPD Medicine Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
    • 5.3. Global COPD Medicine (Volume)
      • 5.3.1. Global COPD Medicine by: Type (Volume)
        • 5.3.1.1. Emphysema
        • 5.3.1.2. Chronic bronchitis
      • 5.3.2. Global COPD Medicine by: Type (Volume)
        • 5.3.2.1. Emphysema
        • 5.3.2.2. Chronic bronchitis
      • 5.3.3. Global COPD Medicine by: Route of Administration (Volume)
        • 5.3.3.1. Inhalation
        • 5.3.3.2. Enteral
        • 5.3.3.3. Parenteral
      • 5.3.4. Global COPD Medicine by: Distribution Channel (Volume)
        • 5.3.4.1. Hospital pharmacy
        • 5.3.4.2. Retail pharmacy
        • 5.3.4.3. Online pharmacy
        • 5.3.4.4. Others
      • 5.3.5. Global COPD Medicine by: Treatment Type (Volume)
        • 5.3.5.1. Drugs
        • 5.3.5.2. 1. Bronchodilator Monotherapy
        • 5.3.5.3. • Short-Acting Beta2-Agonists (SABAs)
        • 5.3.5.4. • Long-Acting Beta2-Agonists (LABAs)
        • 5.3.5.5. • Anti-Cholinergic Agents
        • 5.3.5.6. 2. Anti-Inflammatory Drugs
        • 5.3.5.7. • Oral and Inhaled Corticosteroids
        • 5.3.5.8. • Anti-Leukotrienes
        • 5.3.5.9. Surgery
        • 5.3.5.10. • Lung Volume Reduction Surgery (LVRS)
        • 5.3.5.11. • Lung Transplant
        • 5.3.5.12. • Bullectomy
        • 5.3.5.13. • Others
        • 5.3.5.14. Oxygen Therapy
      • 5.3.6. Global COPD Medicine by: Drug Class (Volume)
        • 5.3.6.1. Bronchodilators drugs
        • 5.3.6.2. Steroids drugs
        • 5.3.6.3. Combination
      • 5.3.7. Global COPD Medicine Region
        • 5.3.7.1. South America
          • 5.3.7.1.1. Brazil
          • 5.3.7.1.2. Argentina
          • 5.3.7.1.3. Rest of South America
        • 5.3.7.2. Asia Pacific
          • 5.3.7.2.1. China
          • 5.3.7.2.2. Japan
          • 5.3.7.2.3. India
          • 5.3.7.2.4. South Korea
          • 5.3.7.2.5. Taiwan
          • 5.3.7.2.6. Australia
          • 5.3.7.2.7. Rest of Asia-Pacific
        • 5.3.7.3. Europe
          • 5.3.7.3.1. Germany
          • 5.3.7.3.2. France
          • 5.3.7.3.3. Italy
          • 5.3.7.3.4. United Kingdom
          • 5.3.7.3.5. Netherlands
          • 5.3.7.3.6. Rest of Europe
        • 5.3.7.4. MEA
          • 5.3.7.4.1. Middle East
          • 5.3.7.4.2. Africa
        • 5.3.7.5. North America
          • 5.3.7.5.1. United States
          • 5.3.7.5.2. Canada
          • 5.3.7.5.3. Mexico
    • 5.4. Global COPD Medicine (Price)
  • 6. COPD Medicine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GSK (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Boehringer Ingelheim (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Roche (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Teva (Israel)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Chiesi (Italy)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mylan (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sumitomo Dainippon (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Merck (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global COPD Medicine Sale, by Type, Route of Administration, Distribution Channel, Treatment Type, Drug Class and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global COPD Medicine (Value)
      • 7.2.1. Global COPD Medicine by: Type (Value)
        • 7.2.1.1. Emphysema
        • 7.2.1.2. Chronic bronchitis
      • 7.2.2. Global COPD Medicine by: Type (Value)
        • 7.2.2.1. Emphysema
        • 7.2.2.2. Chronic bronchitis
      • 7.2.3. Global COPD Medicine by: Route of Administration (Value)
        • 7.2.3.1. Inhalation
        • 7.2.3.2. Enteral
        • 7.2.3.3. Parenteral
      • 7.2.4. Global COPD Medicine by: Distribution Channel (Value)
        • 7.2.4.1. Hospital pharmacy
        • 7.2.4.2. Retail pharmacy
        • 7.2.4.3. Online pharmacy
        • 7.2.4.4. Others
      • 7.2.5. Global COPD Medicine by: Treatment Type (Value)
        • 7.2.5.1. Drugs
        • 7.2.5.2. 1. Bronchodilator Monotherapy
        • 7.2.5.3. • Short-Acting Beta2-Agonists (SABAs)
        • 7.2.5.4. • Long-Acting Beta2-Agonists (LABAs)
        • 7.2.5.5. • Anti-Cholinergic Agents
        • 7.2.5.6. 2. Anti-Inflammatory Drugs
        • 7.2.5.7. • Oral and Inhaled Corticosteroids
        • 7.2.5.8. • Anti-Leukotrienes
        • 7.2.5.9. Surgery
        • 7.2.5.10. • Lung Volume Reduction Surgery (LVRS)
        • 7.2.5.11. • Lung Transplant
        • 7.2.5.12. • Bullectomy
        • 7.2.5.13. • Others
        • 7.2.5.14. Oxygen Therapy
      • 7.2.6. Global COPD Medicine by: Drug Class (Value)
        • 7.2.6.1. Bronchodilators drugs
        • 7.2.6.2. Steroids drugs
        • 7.2.6.3. Combination
      • 7.2.7. Global COPD Medicine Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
    • 7.3. Global COPD Medicine (Volume)
      • 7.3.1. Global COPD Medicine by: Type (Volume)
        • 7.3.1.1. Emphysema
        • 7.3.1.2. Chronic bronchitis
      • 7.3.2. Global COPD Medicine by: Type (Volume)
        • 7.3.2.1. Emphysema
        • 7.3.2.2. Chronic bronchitis
      • 7.3.3. Global COPD Medicine by: Route of Administration (Volume)
        • 7.3.3.1. Inhalation
        • 7.3.3.2. Enteral
        • 7.3.3.3. Parenteral
      • 7.3.4. Global COPD Medicine by: Distribution Channel (Volume)
        • 7.3.4.1. Hospital pharmacy
        • 7.3.4.2. Retail pharmacy
        • 7.3.4.3. Online pharmacy
        • 7.3.4.4. Others
      • 7.3.5. Global COPD Medicine by: Treatment Type (Volume)
        • 7.3.5.1. Drugs
        • 7.3.5.2. 1. Bronchodilator Monotherapy
        • 7.3.5.3. • Short-Acting Beta2-Agonists (SABAs)
        • 7.3.5.4. • Long-Acting Beta2-Agonists (LABAs)
        • 7.3.5.5. • Anti-Cholinergic Agents
        • 7.3.5.6. 2. Anti-Inflammatory Drugs
        • 7.3.5.7. • Oral and Inhaled Corticosteroids
        • 7.3.5.8. • Anti-Leukotrienes
        • 7.3.5.9. Surgery
        • 7.3.5.10. • Lung Volume Reduction Surgery (LVRS)
        • 7.3.5.11. • Lung Transplant
        • 7.3.5.12. • Bullectomy
        • 7.3.5.13. • Others
        • 7.3.5.14. Oxygen Therapy
      • 7.3.6. Global COPD Medicine by: Drug Class (Volume)
        • 7.3.6.1. Bronchodilators drugs
        • 7.3.6.2. Steroids drugs
        • 7.3.6.3. Combination
      • 7.3.7. Global COPD Medicine Region
        • 7.3.7.1. South America
          • 7.3.7.1.1. Brazil
          • 7.3.7.1.2. Argentina
          • 7.3.7.1.3. Rest of South America
        • 7.3.7.2. Asia Pacific
          • 7.3.7.2.1. China
          • 7.3.7.2.2. Japan
          • 7.3.7.2.3. India
          • 7.3.7.2.4. South Korea
          • 7.3.7.2.5. Taiwan
          • 7.3.7.2.6. Australia
          • 7.3.7.2.7. Rest of Asia-Pacific
        • 7.3.7.3. Europe
          • 7.3.7.3.1. Germany
          • 7.3.7.3.2. France
          • 7.3.7.3.3. Italy
          • 7.3.7.3.4. United Kingdom
          • 7.3.7.3.5. Netherlands
          • 7.3.7.3.6. Rest of Europe
        • 7.3.7.4. MEA
          • 7.3.7.4.1. Middle East
          • 7.3.7.4.2. Africa
        • 7.3.7.5. North America
          • 7.3.7.5.1. United States
          • 7.3.7.5.2. Canada
          • 7.3.7.5.3. Mexico
    • 7.4. Global COPD Medicine (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. COPD Medicine: by Type(USD Million)
  • Table 2. COPD Medicine Emphysema , by Region USD Million (2015-2020)
  • Table 3. COPD Medicine Chronic bronchitis , by Region USD Million (2015-2020)
  • Table 4. COPD Medicine: by Type(USD Million)
  • Table 5. COPD Medicine Emphysema , by Region USD Million (2015-2020)
  • Table 6. COPD Medicine Chronic bronchitis , by Region USD Million (2015-2020)
  • Table 7. COPD Medicine: by Route of Administration(USD Million)
  • Table 8. COPD Medicine Inhalation , by Region USD Million (2015-2020)
  • Table 9. COPD Medicine Enteral , by Region USD Million (2015-2020)
  • Table 10. COPD Medicine Parenteral , by Region USD Million (2015-2020)
  • Table 11. COPD Medicine: by Distribution Channel(USD Million)
  • Table 12. COPD Medicine Hospital pharmacy , by Region USD Million (2015-2020)
  • Table 13. COPD Medicine Retail pharmacy , by Region USD Million (2015-2020)
  • Table 14. COPD Medicine Online pharmacy , by Region USD Million (2015-2020)
  • Table 15. COPD Medicine Others , by Region USD Million (2015-2020)
  • Table 16. COPD Medicine: by Treatment Type(USD Million)
  • Table 17. COPD Medicine Drugs , by Region USD Million (2015-2020)
  • Table 18. COPD Medicine 1. Bronchodilator Monotherapy , by Region USD Million (2015-2020)
  • Table 19. COPD Medicine • Short-Acting Beta2-Agonists (SABAs) , by Region USD Million (2015-2020)
  • Table 20. COPD Medicine • Long-Acting Beta2-Agonists (LABAs) , by Region USD Million (2015-2020)
  • Table 21. COPD Medicine • Anti-Cholinergic Agents , by Region USD Million (2015-2020)
  • Table 22. COPD Medicine 2. Anti-Inflammatory Drugs , by Region USD Million (2015-2020)
  • Table 23. COPD Medicine • Oral and Inhaled Corticosteroids , by Region USD Million (2015-2020)
  • Table 24. COPD Medicine • Anti-Leukotrienes , by Region USD Million (2015-2020)
  • Table 25. COPD Medicine Surgery , by Region USD Million (2015-2020)
  • Table 26. COPD Medicine • Lung Volume Reduction Surgery (LVRS) , by Region USD Million (2015-2020)
  • Table 27. COPD Medicine • Lung Transplant , by Region USD Million (2015-2020)
  • Table 28. COPD Medicine • Bullectomy , by Region USD Million (2015-2020)
  • Table 29. COPD Medicine • Others , by Region USD Million (2015-2020)
  • Table 30. COPD Medicine Oxygen Therapy , by Region USD Million (2015-2020)
  • Table 31. COPD Medicine: by Drug Class(USD Million)
  • Table 32. COPD Medicine Bronchodilators drugs , by Region USD Million (2015-2020)
  • Table 33. COPD Medicine Steroids drugs , by Region USD Million (2015-2020)
  • Table 34. COPD Medicine Combination , by Region USD Million (2015-2020)
  • Table 35. South America COPD Medicine, by Country USD Million (2015-2020)
  • Table 36. South America COPD Medicine, by Type USD Million (2015-2020)
  • Table 37. South America COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 38. South America COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 39. South America COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 40. South America COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 41. Brazil COPD Medicine, by Type USD Million (2015-2020)
  • Table 42. Brazil COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 43. Brazil COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 44. Brazil COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 45. Brazil COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 46. Argentina COPD Medicine, by Type USD Million (2015-2020)
  • Table 47. Argentina COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 48. Argentina COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 49. Argentina COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 50. Argentina COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 51. Rest of South America COPD Medicine, by Type USD Million (2015-2020)
  • Table 52. Rest of South America COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 53. Rest of South America COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 54. Rest of South America COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 55. Rest of South America COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 56. Asia Pacific COPD Medicine, by Country USD Million (2015-2020)
  • Table 57. Asia Pacific COPD Medicine, by Type USD Million (2015-2020)
  • Table 58. Asia Pacific COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 59. Asia Pacific COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 60. Asia Pacific COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 61. Asia Pacific COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 62. China COPD Medicine, by Type USD Million (2015-2020)
  • Table 63. China COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 64. China COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 65. China COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 66. China COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 67. Japan COPD Medicine, by Type USD Million (2015-2020)
  • Table 68. Japan COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 69. Japan COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 70. Japan COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 71. Japan COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 72. India COPD Medicine, by Type USD Million (2015-2020)
  • Table 73. India COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 74. India COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 75. India COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 76. India COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 77. South Korea COPD Medicine, by Type USD Million (2015-2020)
  • Table 78. South Korea COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 79. South Korea COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 80. South Korea COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 81. South Korea COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 82. Taiwan COPD Medicine, by Type USD Million (2015-2020)
  • Table 83. Taiwan COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 84. Taiwan COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 85. Taiwan COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 86. Taiwan COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 87. Australia COPD Medicine, by Type USD Million (2015-2020)
  • Table 88. Australia COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 89. Australia COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 90. Australia COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 91. Australia COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 92. Rest of Asia-Pacific COPD Medicine, by Type USD Million (2015-2020)
  • Table 93. Rest of Asia-Pacific COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 94. Rest of Asia-Pacific COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 95. Rest of Asia-Pacific COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 96. Rest of Asia-Pacific COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 97. Europe COPD Medicine, by Country USD Million (2015-2020)
  • Table 98. Europe COPD Medicine, by Type USD Million (2015-2020)
  • Table 99. Europe COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 100. Europe COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 101. Europe COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 102. Europe COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 103. Germany COPD Medicine, by Type USD Million (2015-2020)
  • Table 104. Germany COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 105. Germany COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 106. Germany COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 107. Germany COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 108. France COPD Medicine, by Type USD Million (2015-2020)
  • Table 109. France COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 110. France COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 111. France COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 112. France COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 113. Italy COPD Medicine, by Type USD Million (2015-2020)
  • Table 114. Italy COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 115. Italy COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 116. Italy COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 117. Italy COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 118. United Kingdom COPD Medicine, by Type USD Million (2015-2020)
  • Table 119. United Kingdom COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 120. United Kingdom COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 121. United Kingdom COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 122. United Kingdom COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 123. Netherlands COPD Medicine, by Type USD Million (2015-2020)
  • Table 124. Netherlands COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 125. Netherlands COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 126. Netherlands COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 127. Netherlands COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 128. Rest of Europe COPD Medicine, by Type USD Million (2015-2020)
  • Table 129. Rest of Europe COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 130. Rest of Europe COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 131. Rest of Europe COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 132. Rest of Europe COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 133. MEA COPD Medicine, by Country USD Million (2015-2020)
  • Table 134. MEA COPD Medicine, by Type USD Million (2015-2020)
  • Table 135. MEA COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 136. MEA COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 137. MEA COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 138. MEA COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 139. Middle East COPD Medicine, by Type USD Million (2015-2020)
  • Table 140. Middle East COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 141. Middle East COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 142. Middle East COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 143. Middle East COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 144. Africa COPD Medicine, by Type USD Million (2015-2020)
  • Table 145. Africa COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 146. Africa COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 147. Africa COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 148. Africa COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 149. North America COPD Medicine, by Country USD Million (2015-2020)
  • Table 150. North America COPD Medicine, by Type USD Million (2015-2020)
  • Table 151. North America COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 152. North America COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 153. North America COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 154. North America COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 155. United States COPD Medicine, by Type USD Million (2015-2020)
  • Table 156. United States COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 157. United States COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 158. United States COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 159. United States COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 160. Canada COPD Medicine, by Type USD Million (2015-2020)
  • Table 161. Canada COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 162. Canada COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 163. Canada COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 164. Canada COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 165. Mexico COPD Medicine, by Type USD Million (2015-2020)
  • Table 166. Mexico COPD Medicine, by Route of Administration USD Million (2015-2020)
  • Table 167. Mexico COPD Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 168. Mexico COPD Medicine, by Treatment Type USD Million (2015-2020)
  • Table 169. Mexico COPD Medicine, by Drug Class USD Million (2015-2020)
  • Table 170. COPD Medicine Sales: by Type(K Units)
  • Table 171. COPD Medicine Sales Emphysema , by Region K Units (2015-2020)
  • Table 172. COPD Medicine Sales Chronic bronchitis , by Region K Units (2015-2020)
  • Table 173. COPD Medicine Sales: by Type(K Units)
  • Table 174. COPD Medicine Sales Emphysema , by Region K Units (2015-2020)
  • Table 175. COPD Medicine Sales Chronic bronchitis , by Region K Units (2015-2020)
  • Table 176. COPD Medicine Sales: by Route of Administration(K Units)
  • Table 177. COPD Medicine Sales Inhalation , by Region K Units (2015-2020)
  • Table 178. COPD Medicine Sales Enteral , by Region K Units (2015-2020)
  • Table 179. COPD Medicine Sales Parenteral , by Region K Units (2015-2020)
  • Table 180. COPD Medicine Sales: by Distribution Channel(K Units)
  • Table 181. COPD Medicine Sales Hospital pharmacy , by Region K Units (2015-2020)
  • Table 182. COPD Medicine Sales Retail pharmacy , by Region K Units (2015-2020)
  • Table 183. COPD Medicine Sales Online pharmacy , by Region K Units (2015-2020)
  • Table 184. COPD Medicine Sales Others , by Region K Units (2015-2020)
  • Table 185. COPD Medicine Sales: by Treatment Type(K Units)
  • Table 186. COPD Medicine Sales Drugs , by Region K Units (2015-2020)
  • Table 187. COPD Medicine Sales 1. Bronchodilator Monotherapy , by Region K Units (2015-2020)
  • Table 188. COPD Medicine Sales • Short-Acting Beta2-Agonists (SABAs) , by Region K Units (2015-2020)
  • Table 189. COPD Medicine Sales • Long-Acting Beta2-Agonists (LABAs) , by Region K Units (2015-2020)
  • Table 190. COPD Medicine Sales • Anti-Cholinergic Agents , by Region K Units (2015-2020)
  • Table 191. COPD Medicine Sales 2. Anti-Inflammatory Drugs , by Region K Units (2015-2020)
  • Table 192. COPD Medicine Sales • Oral and Inhaled Corticosteroids , by Region K Units (2015-2020)
  • Table 193. COPD Medicine Sales • Anti-Leukotrienes , by Region K Units (2015-2020)
  • Table 194. COPD Medicine Sales Surgery , by Region K Units (2015-2020)
  • Table 195. COPD Medicine Sales • Lung Volume Reduction Surgery (LVRS) , by Region K Units (2015-2020)
  • Table 196. COPD Medicine Sales • Lung Transplant , by Region K Units (2015-2020)
  • Table 197. COPD Medicine Sales • Bullectomy , by Region K Units (2015-2020)
  • Table 198. COPD Medicine Sales • Others , by Region K Units (2015-2020)
  • Table 199. COPD Medicine Sales Oxygen Therapy , by Region K Units (2015-2020)
  • Table 200. COPD Medicine Sales: by Drug Class(K Units)
  • Table 201. COPD Medicine Sales Bronchodilators drugs , by Region K Units (2015-2020)
  • Table 202. COPD Medicine Sales Steroids drugs , by Region K Units (2015-2020)
  • Table 203. COPD Medicine Sales Combination , by Region K Units (2015-2020)
  • Table 204. South America COPD Medicine Sales, by Country K Units (2015-2020)
  • Table 205. South America COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 206. South America COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 207. South America COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 208. South America COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 209. South America COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 210. Brazil COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 211. Brazil COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 212. Brazil COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 213. Brazil COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 214. Brazil COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 215. Argentina COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 216. Argentina COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 217. Argentina COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 218. Argentina COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 219. Argentina COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 220. Rest of South America COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 221. Rest of South America COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 222. Rest of South America COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 223. Rest of South America COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 224. Rest of South America COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 225. Asia Pacific COPD Medicine Sales, by Country K Units (2015-2020)
  • Table 226. Asia Pacific COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 227. Asia Pacific COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 228. Asia Pacific COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 229. Asia Pacific COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 230. Asia Pacific COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 231. China COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 232. China COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 233. China COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 234. China COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 235. China COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 236. Japan COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 237. Japan COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 238. Japan COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 239. Japan COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 240. Japan COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 241. India COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 242. India COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 243. India COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 244. India COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 245. India COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 246. South Korea COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 247. South Korea COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 248. South Korea COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 249. South Korea COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 250. South Korea COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 251. Taiwan COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 252. Taiwan COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 253. Taiwan COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 254. Taiwan COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 255. Taiwan COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 256. Australia COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 257. Australia COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 258. Australia COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 259. Australia COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 260. Australia COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 261. Rest of Asia-Pacific COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 262. Rest of Asia-Pacific COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 263. Rest of Asia-Pacific COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 264. Rest of Asia-Pacific COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 265. Rest of Asia-Pacific COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 266. Europe COPD Medicine Sales, by Country K Units (2015-2020)
  • Table 267. Europe COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 268. Europe COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 269. Europe COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 270. Europe COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 271. Europe COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 272. Germany COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 273. Germany COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 274. Germany COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 275. Germany COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 276. Germany COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 277. France COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 278. France COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 279. France COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 280. France COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 281. France COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 282. Italy COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 283. Italy COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 284. Italy COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 285. Italy COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 286. Italy COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 287. United Kingdom COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 288. United Kingdom COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 289. United Kingdom COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 290. United Kingdom COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 291. United Kingdom COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 292. Netherlands COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 293. Netherlands COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 294. Netherlands COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 295. Netherlands COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 296. Netherlands COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 297. Rest of Europe COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 298. Rest of Europe COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 299. Rest of Europe COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 300. Rest of Europe COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 301. Rest of Europe COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 302. MEA COPD Medicine Sales, by Country K Units (2015-2020)
  • Table 303. MEA COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 304. MEA COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 305. MEA COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 306. MEA COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 307. MEA COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 308. Middle East COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 309. Middle East COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 310. Middle East COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 311. Middle East COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 312. Middle East COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 313. Africa COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 314. Africa COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 315. Africa COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 316. Africa COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 317. Africa COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 318. North America COPD Medicine Sales, by Country K Units (2015-2020)
  • Table 319. North America COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 320. North America COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 321. North America COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 322. North America COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 323. North America COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 324. United States COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 325. United States COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 326. United States COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 327. United States COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 328. United States COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 329. Canada COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 330. Canada COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 331. Canada COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 332. Canada COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 333. Canada COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 334. Mexico COPD Medicine Sales, by Type K Units (2015-2020)
  • Table 335. Mexico COPD Medicine Sales, by Route of Administration K Units (2015-2020)
  • Table 336. Mexico COPD Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 337. Mexico COPD Medicine Sales, by Treatment Type K Units (2015-2020)
  • Table 338. Mexico COPD Medicine Sales, by Drug Class K Units (2015-2020)
  • Table 339. Company Basic Information, Sales Area and Its Competitors
  • Table 340. Company Basic Information, Sales Area and Its Competitors
  • Table 341. Company Basic Information, Sales Area and Its Competitors
  • Table 342. Company Basic Information, Sales Area and Its Competitors
  • Table 343. Company Basic Information, Sales Area and Its Competitors
  • Table 344. Company Basic Information, Sales Area and Its Competitors
  • Table 345. Company Basic Information, Sales Area and Its Competitors
  • Table 346. Company Basic Information, Sales Area and Its Competitors
  • Table 347. Company Basic Information, Sales Area and Its Competitors
  • Table 348. Company Basic Information, Sales Area and Its Competitors
  • Table 349. COPD Medicine: by Type(USD Million)
  • Table 350. COPD Medicine Emphysema , by Region USD Million (2021-2026)
  • Table 351. COPD Medicine Chronic bronchitis , by Region USD Million (2021-2026)
  • Table 352. COPD Medicine: by Type(USD Million)
  • Table 353. COPD Medicine Emphysema , by Region USD Million (2021-2026)
  • Table 354. COPD Medicine Chronic bronchitis , by Region USD Million (2021-2026)
  • Table 355. COPD Medicine: by Route of Administration(USD Million)
  • Table 356. COPD Medicine Inhalation , by Region USD Million (2021-2026)
  • Table 357. COPD Medicine Enteral , by Region USD Million (2021-2026)
  • Table 358. COPD Medicine Parenteral , by Region USD Million (2021-2026)
  • Table 359. COPD Medicine: by Distribution Channel(USD Million)
  • Table 360. COPD Medicine Hospital pharmacy , by Region USD Million (2021-2026)
  • Table 361. COPD Medicine Retail pharmacy , by Region USD Million (2021-2026)
  • Table 362. COPD Medicine Online pharmacy , by Region USD Million (2021-2026)
  • Table 363. COPD Medicine Others , by Region USD Million (2021-2026)
  • Table 364. COPD Medicine: by Treatment Type(USD Million)
  • Table 365. COPD Medicine Drugs , by Region USD Million (2021-2026)
  • Table 366. COPD Medicine 1. Bronchodilator Monotherapy , by Region USD Million (2021-2026)
  • Table 367. COPD Medicine • Short-Acting Beta2-Agonists (SABAs) , by Region USD Million (2021-2026)
  • Table 368. COPD Medicine • Long-Acting Beta2-Agonists (LABAs) , by Region USD Million (2021-2026)
  • Table 369. COPD Medicine • Anti-Cholinergic Agents , by Region USD Million (2021-2026)
  • Table 370. COPD Medicine 2. Anti-Inflammatory Drugs , by Region USD Million (2021-2026)
  • Table 371. COPD Medicine • Oral and Inhaled Corticosteroids , by Region USD Million (2021-2026)
  • Table 372. COPD Medicine • Anti-Leukotrienes , by Region USD Million (2021-2026)
  • Table 373. COPD Medicine Surgery , by Region USD Million (2021-2026)
  • Table 374. COPD Medicine • Lung Volume Reduction Surgery (LVRS) , by Region USD Million (2021-2026)
  • Table 375. COPD Medicine • Lung Transplant , by Region USD Million (2021-2026)
  • Table 376. COPD Medicine • Bullectomy , by Region USD Million (2021-2026)
  • Table 377. COPD Medicine • Others , by Region USD Million (2021-2026)
  • Table 378. COPD Medicine Oxygen Therapy , by Region USD Million (2021-2026)
  • Table 379. COPD Medicine: by Drug Class(USD Million)
  • Table 380. COPD Medicine Bronchodilators drugs , by Region USD Million (2021-2026)
  • Table 381. COPD Medicine Steroids drugs , by Region USD Million (2021-2026)
  • Table 382. COPD Medicine Combination , by Region USD Million (2021-2026)
  • Table 383. South America COPD Medicine, by Country USD Million (2021-2026)
  • Table 384. South America COPD Medicine, by Type USD Million (2021-2026)
  • Table 385. South America COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 386. South America COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 387. South America COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 388. South America COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 389. Brazil COPD Medicine, by Type USD Million (2021-2026)
  • Table 390. Brazil COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 391. Brazil COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 392. Brazil COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 393. Brazil COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 394. Argentina COPD Medicine, by Type USD Million (2021-2026)
  • Table 395. Argentina COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 396. Argentina COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 397. Argentina COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 398. Argentina COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 399. Rest of South America COPD Medicine, by Type USD Million (2021-2026)
  • Table 400. Rest of South America COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 401. Rest of South America COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 402. Rest of South America COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 403. Rest of South America COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 404. Asia Pacific COPD Medicine, by Country USD Million (2021-2026)
  • Table 405. Asia Pacific COPD Medicine, by Type USD Million (2021-2026)
  • Table 406. Asia Pacific COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 407. Asia Pacific COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 408. Asia Pacific COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 409. Asia Pacific COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 410. China COPD Medicine, by Type USD Million (2021-2026)
  • Table 411. China COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 412. China COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 413. China COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 414. China COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 415. Japan COPD Medicine, by Type USD Million (2021-2026)
  • Table 416. Japan COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 417. Japan COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 418. Japan COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 419. Japan COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 420. India COPD Medicine, by Type USD Million (2021-2026)
  • Table 421. India COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 422. India COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 423. India COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 424. India COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 425. South Korea COPD Medicine, by Type USD Million (2021-2026)
  • Table 426. South Korea COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 427. South Korea COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 428. South Korea COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 429. South Korea COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 430. Taiwan COPD Medicine, by Type USD Million (2021-2026)
  • Table 431. Taiwan COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 432. Taiwan COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 433. Taiwan COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 434. Taiwan COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 435. Australia COPD Medicine, by Type USD Million (2021-2026)
  • Table 436. Australia COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 437. Australia COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 438. Australia COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 439. Australia COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 440. Rest of Asia-Pacific COPD Medicine, by Type USD Million (2021-2026)
  • Table 441. Rest of Asia-Pacific COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 442. Rest of Asia-Pacific COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 443. Rest of Asia-Pacific COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 444. Rest of Asia-Pacific COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 445. Europe COPD Medicine, by Country USD Million (2021-2026)
  • Table 446. Europe COPD Medicine, by Type USD Million (2021-2026)
  • Table 447. Europe COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 448. Europe COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 449. Europe COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 450. Europe COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 451. Germany COPD Medicine, by Type USD Million (2021-2026)
  • Table 452. Germany COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 453. Germany COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 454. Germany COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 455. Germany COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 456. France COPD Medicine, by Type USD Million (2021-2026)
  • Table 457. France COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 458. France COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 459. France COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 460. France COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 461. Italy COPD Medicine, by Type USD Million (2021-2026)
  • Table 462. Italy COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 463. Italy COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 464. Italy COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 465. Italy COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 466. United Kingdom COPD Medicine, by Type USD Million (2021-2026)
  • Table 467. United Kingdom COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 468. United Kingdom COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 469. United Kingdom COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 470. United Kingdom COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 471. Netherlands COPD Medicine, by Type USD Million (2021-2026)
  • Table 472. Netherlands COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 473. Netherlands COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 474. Netherlands COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 475. Netherlands COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 476. Rest of Europe COPD Medicine, by Type USD Million (2021-2026)
  • Table 477. Rest of Europe COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 478. Rest of Europe COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 479. Rest of Europe COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 480. Rest of Europe COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 481. MEA COPD Medicine, by Country USD Million (2021-2026)
  • Table 482. MEA COPD Medicine, by Type USD Million (2021-2026)
  • Table 483. MEA COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 484. MEA COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 485. MEA COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 486. MEA COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 487. Middle East COPD Medicine, by Type USD Million (2021-2026)
  • Table 488. Middle East COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 489. Middle East COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 490. Middle East COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 491. Middle East COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 492. Africa COPD Medicine, by Type USD Million (2021-2026)
  • Table 493. Africa COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 494. Africa COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 495. Africa COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 496. Africa COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 497. North America COPD Medicine, by Country USD Million (2021-2026)
  • Table 498. North America COPD Medicine, by Type USD Million (2021-2026)
  • Table 499. North America COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 500. North America COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 501. North America COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 502. North America COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 503. United States COPD Medicine, by Type USD Million (2021-2026)
  • Table 504. United States COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 505. United States COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 506. United States COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 507. United States COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 508. Canada COPD Medicine, by Type USD Million (2021-2026)
  • Table 509. Canada COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 510. Canada COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 511. Canada COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 512. Canada COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 513. Mexico COPD Medicine, by Type USD Million (2021-2026)
  • Table 514. Mexico COPD Medicine, by Route of Administration USD Million (2021-2026)
  • Table 515. Mexico COPD Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 516. Mexico COPD Medicine, by Treatment Type USD Million (2021-2026)
  • Table 517. Mexico COPD Medicine, by Drug Class USD Million (2021-2026)
  • Table 518. COPD Medicine Sales: by Type(K Units)
  • Table 519. COPD Medicine Sales Emphysema , by Region K Units (2021-2026)
  • Table 520. COPD Medicine Sales Chronic bronchitis , by Region K Units (2021-2026)
  • Table 521. COPD Medicine Sales: by Type(K Units)
  • Table 522. COPD Medicine Sales Emphysema , by Region K Units (2021-2026)
  • Table 523. COPD Medicine Sales Chronic bronchitis , by Region K Units (2021-2026)
  • Table 524. COPD Medicine Sales: by Route of Administration(K Units)
  • Table 525. COPD Medicine Sales Inhalation , by Region K Units (2021-2026)
  • Table 526. COPD Medicine Sales Enteral , by Region K Units (2021-2026)
  • Table 527. COPD Medicine Sales Parenteral , by Region K Units (2021-2026)
  • Table 528. COPD Medicine Sales: by Distribution Channel(K Units)
  • Table 529. COPD Medicine Sales Hospital pharmacy , by Region K Units (2021-2026)
  • Table 530. COPD Medicine Sales Retail pharmacy , by Region K Units (2021-2026)
  • Table 531. COPD Medicine Sales Online pharmacy , by Region K Units (2021-2026)
  • Table 532. COPD Medicine Sales Others , by Region K Units (2021-2026)
  • Table 533. COPD Medicine Sales: by Treatment Type(K Units)
  • Table 534. COPD Medicine Sales Drugs , by Region K Units (2021-2026)
  • Table 535. COPD Medicine Sales 1. Bronchodilator Monotherapy , by Region K Units (2021-2026)
  • Table 536. COPD Medicine Sales • Short-Acting Beta2-Agonists (SABAs) , by Region K Units (2021-2026)
  • Table 537. COPD Medicine Sales • Long-Acting Beta2-Agonists (LABAs) , by Region K Units (2021-2026)
  • Table 538. COPD Medicine Sales • Anti-Cholinergic Agents , by Region K Units (2021-2026)
  • Table 539. COPD Medicine Sales 2. Anti-Inflammatory Drugs , by Region K Units (2021-2026)
  • Table 540. COPD Medicine Sales • Oral and Inhaled Corticosteroids , by Region K Units (2021-2026)
  • Table 541. COPD Medicine Sales • Anti-Leukotrienes , by Region K Units (2021-2026)
  • Table 542. COPD Medicine Sales Surgery , by Region K Units (2021-2026)
  • Table 543. COPD Medicine Sales • Lung Volume Reduction Surgery (LVRS) , by Region K Units (2021-2026)
  • Table 544. COPD Medicine Sales • Lung Transplant , by Region K Units (2021-2026)
  • Table 545. COPD Medicine Sales • Bullectomy , by Region K Units (2021-2026)
  • Table 546. COPD Medicine Sales • Others , by Region K Units (2021-2026)
  • Table 547. COPD Medicine Sales Oxygen Therapy , by Region K Units (2021-2026)
  • Table 548. COPD Medicine Sales: by Drug Class(K Units)
  • Table 549. COPD Medicine Sales Bronchodilators drugs , by Region K Units (2021-2026)
  • Table 550. COPD Medicine Sales Steroids drugs , by Region K Units (2021-2026)
  • Table 551. COPD Medicine Sales Combination , by Region K Units (2021-2026)
  • Table 552. South America COPD Medicine Sales, by Country K Units (2021-2026)
  • Table 553. South America COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 554. South America COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 555. South America COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 556. South America COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 557. South America COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 558. Brazil COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 559. Brazil COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 560. Brazil COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 561. Brazil COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 562. Brazil COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 563. Argentina COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 564. Argentina COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 565. Argentina COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 566. Argentina COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 567. Argentina COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 568. Rest of South America COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 569. Rest of South America COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 570. Rest of South America COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 571. Rest of South America COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 572. Rest of South America COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 573. Asia Pacific COPD Medicine Sales, by Country K Units (2021-2026)
  • Table 574. Asia Pacific COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 575. Asia Pacific COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 576. Asia Pacific COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 577. Asia Pacific COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 578. Asia Pacific COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 579. China COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 580. China COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 581. China COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 582. China COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 583. China COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 584. Japan COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 585. Japan COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 586. Japan COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 587. Japan COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 588. Japan COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 589. India COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 590. India COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 591. India COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 592. India COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 593. India COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 594. South Korea COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 595. South Korea COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 596. South Korea COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 597. South Korea COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 598. South Korea COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 599. Taiwan COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 600. Taiwan COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 601. Taiwan COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 602. Taiwan COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 603. Taiwan COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 604. Australia COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 605. Australia COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 606. Australia COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 607. Australia COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 608. Australia COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 609. Rest of Asia-Pacific COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 610. Rest of Asia-Pacific COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 611. Rest of Asia-Pacific COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 612. Rest of Asia-Pacific COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 613. Rest of Asia-Pacific COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 614. Europe COPD Medicine Sales, by Country K Units (2021-2026)
  • Table 615. Europe COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 616. Europe COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 617. Europe COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 618. Europe COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 619. Europe COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 620. Germany COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 621. Germany COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 622. Germany COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 623. Germany COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 624. Germany COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 625. France COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 626. France COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 627. France COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 628. France COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 629. France COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 630. Italy COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 631. Italy COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 632. Italy COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 633. Italy COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 634. Italy COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 635. United Kingdom COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 636. United Kingdom COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 637. United Kingdom COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 638. United Kingdom COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 639. United Kingdom COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 640. Netherlands COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 641. Netherlands COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 642. Netherlands COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 643. Netherlands COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 644. Netherlands COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 645. Rest of Europe COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 646. Rest of Europe COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 647. Rest of Europe COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 648. Rest of Europe COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 649. Rest of Europe COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 650. MEA COPD Medicine Sales, by Country K Units (2021-2026)
  • Table 651. MEA COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 652. MEA COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 653. MEA COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 654. MEA COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 655. MEA COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 656. Middle East COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 657. Middle East COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 658. Middle East COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 659. Middle East COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 660. Middle East COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 661. Africa COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 662. Africa COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 663. Africa COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 664. Africa COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 665. Africa COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 666. North America COPD Medicine Sales, by Country K Units (2021-2026)
  • Table 667. North America COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 668. North America COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 669. North America COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 670. North America COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 671. North America COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 672. United States COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 673. United States COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 674. United States COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 675. United States COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 676. United States COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 677. Canada COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 678. Canada COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 679. Canada COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 680. Canada COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 681. Canada COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 682. Mexico COPD Medicine Sales, by Type K Units (2021-2026)
  • Table 683. Mexico COPD Medicine Sales, by Route of Administration K Units (2021-2026)
  • Table 684. Mexico COPD Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 685. Mexico COPD Medicine Sales, by Treatment Type K Units (2021-2026)
  • Table 686. Mexico COPD Medicine Sales, by Drug Class K Units (2021-2026)
  • Table 687. Research Programs/Design for This Report
  • Table 688. Key Data Information from Secondary Sources
  • Table 689. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global COPD Medicine: by Type USD Million (2015-2020)
  • Figure 5. Global COPD Medicine: by Type USD Million (2015-2020)
  • Figure 6. Global COPD Medicine: by Route of Administration USD Million (2015-2020)
  • Figure 7. Global COPD Medicine: by Distribution Channel USD Million (2015-2020)
  • Figure 8. Global COPD Medicine: by Treatment Type USD Million (2015-2020)
  • Figure 9. Global COPD Medicine: by Drug Class USD Million (2015-2020)
  • Figure 10. South America COPD Medicine Share (%), by Country
  • Figure 11. Asia Pacific COPD Medicine Share (%), by Country
  • Figure 12. Europe COPD Medicine Share (%), by Country
  • Figure 13. MEA COPD Medicine Share (%), by Country
  • Figure 14. North America COPD Medicine Share (%), by Country
  • Figure 15. Global COPD Medicine: by Type K Units (2015-2020)
  • Figure 16. Global COPD Medicine: by Type K Units (2015-2020)
  • Figure 17. Global COPD Medicine: by Route of Administration K Units (2015-2020)
  • Figure 18. Global COPD Medicine: by Distribution Channel K Units (2015-2020)
  • Figure 19. Global COPD Medicine: by Treatment Type K Units (2015-2020)
  • Figure 20. Global COPD Medicine: by Drug Class K Units (2015-2020)
  • Figure 21. South America COPD Medicine Share (%), by Country
  • Figure 22. Asia Pacific COPD Medicine Share (%), by Country
  • Figure 23. Europe COPD Medicine Share (%), by Country
  • Figure 24. MEA COPD Medicine Share (%), by Country
  • Figure 25. North America COPD Medicine Share (%), by Country
  • Figure 26. Global COPD Medicine share by Players 2020 (%)
  • Figure 27. Global COPD Medicine share by Players (Top 3) 2020(%)
  • Figure 28. Global COPD Medicine share by Players (Top 5) 2020(%)
  • Figure 29. BCG Matrix for key Companies
  • Figure 30. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. GSK (United Kingdom) Revenue: by Geography 2020
  • Figure 32. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 34. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Boehringer Ingelheim (Germany) Revenue: by Geography 2020
  • Figure 36. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 37. Roche (Switzerland) Revenue: by Geography 2020
  • Figure 38. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 39. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 40. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 41. Teva (Israel) Revenue: by Geography 2020
  • Figure 42. Chiesi (Italy) Revenue, Net Income and Gross profit
  • Figure 43. Chiesi (Italy) Revenue: by Geography 2020
  • Figure 44. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 45. Mylan (United States) Revenue: by Geography 2020
  • Figure 46. Sumitomo Dainippon (Japan) Revenue, Net Income and Gross profit
  • Figure 47. Sumitomo Dainippon (Japan) Revenue: by Geography 2020
  • Figure 48. Merck (Germany) Revenue, Net Income and Gross profit
  • Figure 49. Merck (Germany) Revenue: by Geography 2020
  • Figure 50. Global COPD Medicine: by Type USD Million (2021-2026)
  • Figure 51. Global COPD Medicine: by Type USD Million (2021-2026)
  • Figure 52. Global COPD Medicine: by Route of Administration USD Million (2021-2026)
  • Figure 53. Global COPD Medicine: by Distribution Channel USD Million (2021-2026)
  • Figure 54. Global COPD Medicine: by Treatment Type USD Million (2021-2026)
  • Figure 55. Global COPD Medicine: by Drug Class USD Million (2021-2026)
  • Figure 56. South America COPD Medicine Share (%), by Country
  • Figure 57. Asia Pacific COPD Medicine Share (%), by Country
  • Figure 58. Europe COPD Medicine Share (%), by Country
  • Figure 59. MEA COPD Medicine Share (%), by Country
  • Figure 60. North America COPD Medicine Share (%), by Country
  • Figure 61. Global COPD Medicine: by Type K Units (2021-2026)
  • Figure 62. Global COPD Medicine: by Type K Units (2021-2026)
  • Figure 63. Global COPD Medicine: by Route of Administration K Units (2021-2026)
  • Figure 64. Global COPD Medicine: by Distribution Channel K Units (2021-2026)
  • Figure 65. Global COPD Medicine: by Treatment Type K Units (2021-2026)
  • Figure 66. Global COPD Medicine: by Drug Class K Units (2021-2026)
  • Figure 67. South America COPD Medicine Share (%), by Country
  • Figure 68. Asia Pacific COPD Medicine Share (%), by Country
  • Figure 69. Europe COPD Medicine Share (%), by Country
  • Figure 70. MEA COPD Medicine Share (%), by Country
  • Figure 71. North America COPD Medicine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GSK (United Kingdom)
  • AstraZeneca (United Kingdom)
  • Boehringer Ingelheim (Germany)
  • Roche (Switzerland)
  • Novartis (Switzerland)
  • Teva (Israel)
  • Chiesi (Italy)
  • Mylan (United States)
  • Sumitomo Dainippon (Japan)
  • Merck (Germany)
Additional players considered in the study are as follows:
Dr. Reddy’s Laboratories Ltd (India) , F. Hoffmann-La Roche Ltd (Switzerland) , Abbott (United States)
Select User Access Type

Key Highlights of Report


Oct 2021 208 Pages 71 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global COPD Medicine Market Quantitative research analysis
Global COPD Medicine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GSK (United Kingdom), AstraZeneca (United Kingdom), Boehringer Ingelheim (Germany), Roche (Switzerland), Novartis (Switzerland), Teva (Israel), Chiesi (Italy), Mylan (United States), Sumitomo Dainippon (Japan) and Merck (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
Analysts at AMA estimates COPD Medicine Market to reach USD Million by 2026.

Know More About Global COPD Medicine Market Report?

Have a Query? Click Here

Other Related Reports

Calcium Malate Comprehensive Study by End Users (Food and Beverages, Pharmaceutical, Nutraceutical, Animal Feed), Distribution Channel (Online (E-Commerce Stores), Offline (Speciality Stores, Hyper M...
$ 3650
Polypill Products Comprehensive Study by Type (Aspirin, Beta-Blockers, Diuretics, Statins, ACE-Inhibitors), Application (Blood Pressure Management, Control Cholesterol Level), Form (Capsules, Tablets...
$ 3450
Mometasone Comprehensive Study by Prescription (Over the Counter, Prescription type), Route of Administration (Topical, Intranasal), Indication (Inflammatory skin disorders, Asthma), Distribution Cha...
$ 3650
Blood Pressure Maintenance Supplements Comprehensive Study by Application (Adults, Pregnant Women, Geriatrics), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drugstores, Online Pharma...
$ 3650
Essential Thrombocythemia Comprehensive Study by Application (Hospitals, Emergency Departments, Clinics, Others), Drug (Aspirin, Hydroxyurea, Anagrelide, Interferon), End Users (Above 60 Years People...
$ 3450
Cushing’s Disease Treatment Comprehensive Study by Drug (Ketoconazole, Mitotane, Aminoglutethimide, Metyrapone, Mifepristone, Etomidate, Pasireotide), Cushing’s Syndrome (Iatrogenic Cushing’s Syndrom...
$ 3650